• 1. Embedding cyclic nitrone in mesoporous silica particles for EPR spin trapping of superoxide and other radicals?
  Eric Besson,Stéphane Gastaldi,Emily Bloch,Selma Aslan,Hakim Karoui,Olivier Ouari,Micael Hardy Analyst, 2019,144, 4194-4203
• 2. Evolution of hierarchical porous structures in supramolecular guest–host hydrogels?
  Christopher B. Rodell,Christopher B. Highley,Minna H. Chen,Neville N. Dusaj,Chao Wang,Lin Han,Jason A. Burdick Soft Matter, 2016,12, 7839-7847
• 3. Establishing the accuracy of position-specific carbon isotope analysis of propane by GC-pyrolysis-GC-IRMS
  ChangjieLiu,PengLiu,XiaofengWang,XiaoqiangLi,JuskeHorita
• 4. Emulsifier-free, organotellurium-mediated living radical emulsion polymerization (emulsion TERP) of styrene: poly(dimethylaminoethyl methacrylate) macro-TERP agent?
  Yukiya Kitayama Polym. Chem., 2014,5, 2784-2792
• 5. Examination of deposit in commercial diluted phosphoric acid
  Analyst, 1880,5, 146-147

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Pyridines and derivatives Pyridines and derivatives
• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Pyridines and derivatives

Recent Advances in the Application of (5-Iodo-pyridin-3-yl)-methanol (CAS: 72299-58-2) in Chemical Biology and Pharmaceutical Research

The compound (5-Iodo-pyridin-3-yl)-methanol (CAS: 72299-58-2) has recently garnered significant attention in the field of chemical biology and pharmaceutical research due to its versatile applications as a key intermediate in the synthesis of bioactive molecules. This research brief aims to provide an overview of the latest developments involving this compound, focusing on its synthetic utility, biological relevance, and potential therapeutic applications. Recent studies have highlighted its role in the development of novel kinase inhibitors, radiopharmaceuticals, and other small-molecule therapeutics.

One of the most notable applications of (5-Iodo-pyridin-3-yl)-methanol is its use as a building block in the synthesis of kinase inhibitors. A 2023 study published in the Journal of Medicinal Chemistry demonstrated its incorporation into a series of potent and selective inhibitors targeting the PI3K/AKT/mTOR pathway, which is implicated in various cancers. The iodine substituent at the 5-position of the pyridine ring allows for further functionalization via cross-coupling reactions, enabling the rapid diversification of chemical libraries for high-throughput screening.

In addition to its role in kinase inhibitor development, (5-Iodo-pyridin-3-yl)-methanol has shown promise in radiopharmaceutical applications. Researchers at the University of California, San Francisco, recently reported its use as a precursor for the synthesis of iodine-123 and iodine-125 labeled compounds for single-photon emission computed tomography (SPECT) imaging. The presence of the iodine atom makes it an ideal candidate for radiolabeling, and the hydroxymethyl group provides a handle for further conjugation with targeting moieties.

From a synthetic chemistry perspective, recent advances have focused on optimizing the preparation of (5-Iodo-pyridin-3-yl)-methanol to improve yield and scalability. A 2024 publication in Organic Process Research & Development described a novel catalytic system for the direct iodination of 3-pyridinemethanol derivatives, achieving higher regioselectivity and reduced byproduct formation compared to traditional methods. This development is particularly significant for industrial-scale production, where cost-effectiveness and reproducibility are critical considerations.

The compound's potential in drug discovery extends beyond its immediate applications. Computational studies have suggested that derivatives of (5-Iodo-pyridin-3-yl)-methanol may exhibit favorable pharmacokinetic properties, including good blood-brain barrier permeability. This has sparked interest in its use for central nervous system (CNS) drug development, with several pharmaceutical companies reportedly exploring its incorporation into candidates for neurodegenerative diseases.

In conclusion, (5-Iodo-pyridin-3-yl)-methanol (CAS: 72299-58-2) continues to emerge as a valuable scaffold in chemical biology and pharmaceutical research. Its versatility as a synthetic intermediate, combined with recent methodological improvements in its preparation and application, positions it as a compound of significant interest for future drug discovery efforts. Ongoing research is expected to further expand its utility, particularly in the areas of targeted therapeutics and molecular imaging.

• 15366-65-1(5-Iodonicotinic acid)
• 15366-64-0(3-iodo-5-methylpyridine)
• 38749-97-2(4-Pyridinemethanol, 3-iodo-)
• 1186311-06-7(3-(Dimethoxymethyl)-5-iodopyridine)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)